Cancer Causes & Control

, Volume 17, Issue 4, pp 403–409 | Cite as

Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)

  • Rosemary D. CressEmail author
  • Daixin Yin
  • Lisa Clarke
  • Richard Bold
  • Elizabeth A. Holly
Original Paper



The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.


Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000. Demographic, tumor and treatment information was extracted from the CCR, and socioeconomic status (SES) was assigned based on census block group of residence.


A total of 10,612 eligible patients were identified of whom 1674 (15.8%) underwent surgical resection. Patients of lower SES were less likely to undergo resection and somewhat less likely to survive. Median survival was 3.5 months for patients who were not resected and 13.3 months for those who underwent resection. Adjuvant therapy was associated with a decreased risk of death among patients who underwent resection.


This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population. Median survival was shorter than that reported from other series. Race/ethnicity did not have a significant effect on survival. However patients residing in poor neighborhoods were less likely to undergo resection and somewhat less likely to survive this disease.


Pancreatic neoplasms Survival Social class Registries 



The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885, the National Cancer Institute’s Surveillance, Epidemiology and End Results Program, and the Centers for Disease Control and Prevention National Program of Cancer Registries. The ideas and opinions expressed herein are those of the author and endorsement by the State of California, Department of Health Services, the National Cancer Institute and the Centers for Disease Control and Prevention is not intended nor should be inferred.


  1. 1.
    Tucker T, Howe H, Weir H (1999) Certification for population-based cancer registries. J Registry Manage 26:24–27Google Scholar
  2. 2.
    Stewart S, Glaser S, Horn-Ross P, West D (1993) SEER study of methods to classify Hispanic cancer patients (Final Report: Contract N01-CN-05224). In Edition Union City, CA: Northern California Cancer CenterGoogle Scholar
  3. 3.
    Kwong S, Perkins C, Morris C et al. (2001) Cancer in California: 1988–1999. In Edition Sacramento, CA: California Department of Health Services, Cancer Surveillance SectionGoogle Scholar
  4. 4.
    Shambaugh E, Ries L, Young J et al. (1992) SEER Extent of Disease – 1988 Codes and Coding InstructionsGoogle Scholar
  5. 5.
    Seiffert J, ed. (1993) SEER Program: comparative staging guide for cancer, version 1.1. National Cancer InstituteGoogle Scholar
  6. 6.
    Young J, Roffers S, Ries L et al. (2001) SEER Summary Staging Manual – 2000. Codes and Coding Instructions, National Cancer Institute, Bethesda, MDGoogle Scholar
  7. 7.
    Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology, 2nd Edition. Geneva: World Health OrganizationGoogle Scholar
  8. 8.
    Yost K, Perkins C, Cohen R et al. (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMedGoogle Scholar
  9. 9.
    Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  10. 10.
    Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMedGoogle Scholar
  11. 11.
    Cox D (1972) Regression models and life tables. J R Stat Soc 34:187–202Google Scholar
  12. 12.
    Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85PubMedGoogle Scholar
  13. 13.
    Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939–945CrossRefPubMedGoogle Scholar
  14. 14.
    Warren JL, Klabunde CN, Schrag D et al. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18Google Scholar
  15. 15.
    Tsiotos GG, Farnell MB, Sarr MG (1999) Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 23:913–919CrossRefPubMedGoogle Scholar
  16. 16.
    Bachmann MO, Alderson D, Peters TJ et al. (2003) Influence of specialization on the management and outcome of patients with pancreatic cancer. Br J Surg 90:171–177CrossRefPubMedGoogle Scholar
  17. 17.
    Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76:1671–1677PubMedGoogle Scholar
  18. 18.
    Nitecki SS, Sarr MG, Colby TV, van Heerden JA (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221:59–66PubMedGoogle Scholar
  19. 19.
    Gudjonsson B (2002) Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol 35:180–184CrossRefPubMedGoogle Scholar
  20. 20.
    Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279PubMedGoogle Scholar
  21. 21.
    Kuhlmann KF, de Castro SM, Wesseling JG et al. (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40:549–558CrossRefPubMedGoogle Scholar
  22. 22.
    Cleary SP, Gryfe R, Guindi M et al. (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731CrossRefPubMedGoogle Scholar
  23. 23.
    Choti MA (2004) Adjuvant therapy for pancreatic cancer–the debate continues. N Engl J Med 350:1249–1251CrossRefPubMedGoogle Scholar
  24. 24.
    Cress RD, Zaslavsky AM, West DW et al. (2003) Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care 41:1006–1012PubMedGoogle Scholar
  25. 25.
    Yeo CJ, Abrams RA, Grochow LB et al. (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–633; discussion 633–626CrossRefPubMedGoogle Scholar
  26. 26.
    Sohn TA, Yeo CJ, Cameron JL et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Rosemary D. Cress
    • 1
    • 2
    • 5
    Email author
  • Daixin Yin
    • 1
  • Lisa Clarke
    • 1
  • Richard Bold
    • 3
  • Elizabeth A. Holly
    • 4
  1. 1.California Cancer RegistryPublic Health InstituteSacramentoUSA
  2. 2.Department of Public Health Sciences, Division of EpidemiologyUC DavisSacramentoUSA
  3. 3.Division of Surgical OncologyUC Davis Medical CenterDavisUSA
  4. 4.Department of Epidemiology and Biostatistics, Division of Cancer EpidemiologyUC San FranciscoSan FranciscoUSA
  5. 5.SacramentoUSA

Personalised recommendations